X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Clinical Trials

EU Authorities Outline A New Clinical Research Timeline

Content Team by Content Team
13th September 2022
in Clinical Trials, News
EU Authorities

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The European Commission (EC), Heads of Medicine Agencies (HMA), and European Medicines Agency (EMA) have released the 2022–2026 workplan for the programme Accelerating Clinical Trials in the EU (ACT EU).

Building on the Clinical Trials Regulation (CTR) and Clinical Trials Information System (CTIS), which went into effect in the same month, ACT EU was established in January with the goal of revolutionising the way clinical trials are started, planned, and conducted.

The goal is to strengthen the EU’s position as a hub for clinical research, encourage the creation of high-quality, risk-free, and efficient medicines, and enhance the integration of clinical research into the European healthcare system. The project intends to retain the high degree of security for study subjects, data integrity, and openness while also improving the European ecosystem for clinical trials. The multi-annual ACT EU workplan includes important focus areas such as innovative clinical trials, reliable procedures, and stakeholder participation.

For 2023, the new workplan specifies the following deliverables and deadlines:

  • Creating a support system expressly for academic sponsors to increase the EU’s appeal as a location for large, international clinical trials.
  • Focus on CTIS and CTR training activities and problem-solving any challenges trial sponsors may run across while putting the CTR into practise.
  • Creating a multi-stakeholder platform that would enable regular communication between all stakeholders, such as patients, healthcare workers, and academics, to assist the advancement of the clinical trials setting.
  • Modernising best practises in clinical care by promoting the adoption and application of updated EU standards for technology and clinical trial design.
  • To identify and prioritise improvements in clinical trial procedures, release guidelines on decentralized clinical studies by the end of 2022.

The ACT EU workplan, which was developed based on the conclusions of the European Medicines Agencies Network Strategy to 2025 and the European Commission’s Pharmaceutical Strategy for Europe, lists the 10 main tasks for ACT EU.

Previous Post

Dupixent Charts A Win Before The FDA Prurigo Nodularis Order

Next Post

Fresh Lumakras Lung Cancer Data From Amgen Fuel KRAS Dispute

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Fresh Lumakras Lung Cancer Data From Amgen Fuel KRAS Dispute

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In